Hyperhomocysteinemia: A risk factor for cardiovascular disease … Influence of sex hormones on homocysteine metabolism

References

• Mudd S. H., Levy H. L., Skovby F. Disorders of transsulfuration. The Metabolic Basis of Inherited Disease, 6th edition, C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle. McGraw-Hill, New York 1989; 693–734
   Google Scholar
• Rosenblatt D. S. Inherited disorders of folate transport and metabolism. The Metabolic Basis of Inherited Disease, 6th edition, C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle. McGraw-Hill, New York 1989; 2049–64
   Google Scholar
• Kraus J. P. Molecular basis of phenotype expression in homocystinuria. J. Inher. Metab. Dis. 1994; 17: 383–90
   Google Scholar
• Kluijtmans L. A.J., Blom H. J., Boers G. H.J., VanOost B. A., Trijbels J. M.F., VandenHeuvel L. P.W.J. Two novel missense mutations in the cystathonine β-synthase gene in homocystinuric patients. Hum. Genet. 1995; 96: 249–50
   Google Scholar
• Goyette P., Frosst P., Rosenblatt D. S., Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am. J. Hum. Genet. 1995; 56: 1052–9
   PubMed Web of Science ®Google Scholar
• McCully K. S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 1969; 56: 111–28
   PubMed Web of Science ®Google Scholar
• Boers G. H.J., Smals A. G. H., Trijbels J. M.F., Fowler B., Bakkeren J. A. J. M., Schoonderwaldt H. C., Kleijer W. J., Kloppenborg P. W.C. Heterozygosity for homocystinuria in peripheral and cerebral occlusive arterial disease. N. Engl. J. Men. 1985; 313: 709–15
   PubMed Web of Science ®Google Scholar
• Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 1991; 324: 1149–55
   PubMed Web of Science ®Google Scholar
• Ueland P. M., Refsum H., Brattstrom L. Plasma homocysteine and cardiovascular disease. Artherosclerotic Cardiovascular Disease, Hemostasis and Endothelial Function, R. B. Francis. Marcel Dekker Inc., New York 1992; 183–236
   Google Scholar
• DenHeijer M., Blom H. J., Gerrits W. B.J., Rosendaal F. R., Bos G. M.J. Hyperhomocysteinemia: a risk factor for recurrent venous thrombosis. Lancet 1995; 345: 882–5
   Google Scholar
• Wouters M. G.A.J., Boers G. H.J., Blom H. J., Trijbels J. M.F., Thomas C. M.G., Borm G. F., Steegers-Theunissen R. P. M., Eskes T. K.A.B. Hyperhomocysteinemia: a risk factor in women with unexplained recurrent early pregnancy loss. Fertil. Steril. 1993; 60: 820–5
   PubMed Web of Science ®Google Scholar
• VanderPut N. J.M., Steegers-Theunissen R. P.M., Frosst P., Trijbels J. M.F., Eskes T. K.A.B., VandenHeuvel L. P., Mariman E. C.M., DenHeijer M., Rozen R., Blom H. J. Mutated methylenetetrahydrofolate reductase as a risk-factor for spina bifida. Lancet 1995; 246: 1070–2
   Google Scholar
• Finkelstein J. D. Methonine metabolism in mammals. J. Nutr. 1990; 1: 228–37
   Google Scholar
• Mudd S. H., Havlik R., Levy H. L., McKusick V. A., Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria. Am. J. Hum. Genet. 1981; 33: 883–93
   Google Scholar
• Daly L., Robinson K., Tan K. S., Graham I. Hyperhomocysteinemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences. Q. J. Med. 1993; 86: 685–9
   Google Scholar
• Engbersen A. M. T., Franken D. G., Boers G. H.J., Stevens E. M. B., Trijbels J. M.F., Blom H. J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am. J. Hum. Genet. 1995; 56: 142–50
   PubMed Web of Science ®Google Scholar
• Kluijtmans L. A.J., VandenHeuvel L. P.W.J., Boers G. H.J., Frosst P., VanOost B. A., DenHeijer M., Stevens E. M. B., Trijbels J. M.F., Rozen R., Blom H. J. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am.J. Hum. Grnet.
   Google Scholar
• Kozich V., Kraus E., DeFranchis R., Fowler B., Boers G. H.J., Graham I., Kraus J. P. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine β-synthase alleles at the molecular level. Hum. Mol. Genet. 1995; 4: 623–9
   PubMedGoogle Scholar
• Kang S. S., Wong P. W. K., Susmano A., Sora J., Norusis M., Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am. J. Hum. Genet. 1991; 48: 536–45
   PubMed Web of Science ®Google Scholar
• Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. H.J., DenHeijer M., Kluijtmans L. A.J., VandenHeuvel L. P., Rozen R. Identification of a candidate genetic risk factor for vascular disease: a common mutation at the methylenetetrahydrofolate reductase locus. Nature Genet. 1995; 10: 111–13
   PubMed Web of Science ®Google Scholar
• Mudd S. H., Skovby F., Levy H., et al. The natural history of homocystinuria due to cystanthionine β-synthase deficiency. Am. J. Hum. Genet. 1985; 37: 1–31
   PubMed Web of Science ®Google Scholar
• Franken D. G., Boers G. H.J., Blom H. J., Trijbels J. M.F., Kloppenborg P. W.C. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler. Thromb. 1994; 14: 465–70
   PubMed Web of Science ®Google Scholar
• Brattström L., Israelsson B., Norrving B., Bergqvist D., Thörne J., Hultberg B., Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81: 51–60
   PubMed Web of Science ®Google Scholar
• Boers G. H.J., Smals A. G. H., Trijbels J. M.F., Leermakers A. I., Kloppenborg P. W. Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J. Clin. Invest. 1983; 72, 1971-6
   Google Scholar
• Blom H. J., Boers G. H.J., Van den Elzen J. P. A. M., Van Roessel J. J.M., Trijbels J. M.F., Tangerman A. Differences between premenopausal women and young men in the transamination pathway of methionine catabolism, and the protection against vascular disease. Eur. J. Clin. Invest. 1988; 18: 633–8
   PubMedGoogle Scholar
• Kang S. S., Wong P. W. K., Zhou J., Cook H. Y. Total homocyst(e)ine in plasma and amniotic fluid of pregnant women. Metabolism 1986; 35: 889–91
   PubMed Web of Science ®Google Scholar
• Andersson A., Hultberg B., Brattstrom L., Isaksson A. Decreased serum homocysteine in pregnancy. Eur. J. Clin. Chem. Clin. Biochem. 1992; 30: 377–9
   PubMedGoogle Scholar
• Brattström L. E., Hultberg B. L., Hardebo J. E. Folic acid responsive postmenopausal homocysteinaemia. Metabolism 1985; 34: 1073–7
   Google Scholar
• Kang S. S., Wong P. W. K., Cook H. Y., Norusis M., Messer J. V. Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J. Clin. Invest. 1986; 77: 1482–6
   PubMed Web of Science ®Google Scholar
• Anderson A., Brattstrom L., Israelsson B., Isaksson A., Hamfelt A., Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur. J. Clin. Invest. 1992; 22: 79–87
   Google Scholar
• Dudman N. P. B., Wilcken D. E. L., Wang J., Lynch J. F., Macey D., Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler. Thromb. 1993; 13: 1253–60
   PubMedGoogle Scholar
• Wouters M. G. A. J., Moorrees M. T. E. C., Van der Mooren M. J., Blom H. J., Boers G. H.J., Schellekens L. A., Thomas C. M. G., Eskes T. K.A.B. Plasma homocysteine and menopausal status. Eur. J. Clin. Invest.
   Google Scholar
• Steegers-Theunissen R. P.M., Boers G. H.J., Steegers E. A.P., Trijbels J. M.F., Thomas C. M.G., Eskes T. K.A.B. Effects of sub-50 oral contraceptives on homocysteine metabolism: a preliminary study. Contraception 1992; 45: 129–39
   PubMed Web of Science ®Google Scholar
• Brattström L., Israelsson B., Olsson A., Anderson A., Hultberg B. Plasma homocysteine in women on oral oestrogen-containing contraceptives and in men with oestrogen-treated prostatic carcinoma. Scand. J. Clin. Lab. Invest. 1992; 52: 283–7
   PubMed Web of Science ®Google Scholar
• Van der Mooren M. J., Wouters M. G. A. J., Blom H. J., Schellekens L. A., Eskes T. K. A. B., Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur. J. Clin. Invest. 1994; 24: 733–6
   PubMed Web of Science ®Google Scholar
• Van der Mooren M. J., Wouters M. G.A.J., Blom H. J., Schellekens L. A., Eskes T. K.A.B., Rolland R. Homocysteine concentrations may decrease during postmenopausal hormone replacement therapy. Ir. J. Med. Sci. 1995; 164(Suppl. 15)21
   Google Scholar
• Stampfer M. J., Colditz G. A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 1991; 151: 75–8
   Google Scholar
• Anker G., Lønning P. E., Ueland P. M., Refsum H., Lien E. A. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen. Int. J. Cancer 1995; 60: 365–8
   PubMed Web of Science ®Google Scholar
• Rutquist L. E., Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J. Nut. Cancer Inst. 1993; 85: 1398–406
   Google Scholar